<DOC>
	<DOCNO>NCT01466452</DOCNO>
	<brief_summary>This study randomize open label study implies administration asprin accord three different regimen . The aim study : - establish whether coronary artery bypass surgery / aortic valve replacement surgery bioprostheses associate change rate platelet regeneration reduce effectiveness aspirin administer dose 100mg/die term inhibition platelet biosynthesis thromboxane A2 . - determine whether patient need different ( shorter ) interval administration order completely permanently inhibit platelet COX-1 . The endpoint study : - To evaluate change level TXB2 12-HETE serum 12 24 hour administration aspirin change level 11-dehydro TXB2 urinary 8-iso-PGF2 alpha urinary , 2-3 dinor-6-chetoPGF1 alpha , Verify-NOW Aspirin , platelets crosslinked 12 24 hour administration aspirin</brief_summary>
	<brief_title>Antiplatelet Effect Low Doses Aspirin Taken Every 12 Hours Patients Undergoing Coronary Artery Bypass Graft and/or Aortic Valve Surgery</brief_title>
	<detailed_description />
	<mesh_term>Arteriosclerosis</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>inform consent study sign coronary artery bypass graft / aortic valve replacement surgery bioprostheses age 55 80 ejection fraction &gt; 30 % . excessive bleeding ( &gt; 1000mL / 6 h ) need operation bleed perioperative myocardial infarction stroke renal failure require dialysis need wait postoperative anticoagulation patient undergoing coronary artery bypass graft procedure consequence fail percutaneous coronary intervention patient undergoing offpump coronary artery bypass graft overt kidney liver disease therapy influence coagulation fertile woman</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>